Abstract
Site directed drug delivery with high efficacy is the biggest challenge in the area of current pharmaceuticals. Biodegradable polymer-based controlled release nanoparticle platforms could be beneficial for targeted delivery of therapeutics and contrast agents for a myriad of important human diseases. Biodegradable nanoparticles, which can be engineered to load multiple drugs with varied physicochemical properties, contrast agents, and cellular or intracellular component targeting moieties, have emerged as potential alternatives for tracking and treating human diseases. In this review, we will highlight the current advances in the design and execution of such platforms for their potential application in the diagnosis and treatment of variety of diseases ranging from cancer to Alzheimer’s and we will provide a critical analysis of the associated challenges for their possible clinical translation.
Keywords: Active targeting, biomaterials, blood-brain barrier, cancer, cardiovascular diseases, liposome, neurodegenerative diseases, nanomedicine, nanotechnology, polymer, passive targeting.
Current Medicinal Chemistry
Title:Nanocarriers for Tracking and Treating Diseases
Volume: 20 Issue: 28
Author(s): Sean Marrache, Rakesh Kumar Pathak, Kasey L. Darley, Joshua H. Choi, Dhillon Zaver, Nagesh Kolishetti and Shanta Dhar
Affiliation:
Keywords: Active targeting, biomaterials, blood-brain barrier, cancer, cardiovascular diseases, liposome, neurodegenerative diseases, nanomedicine, nanotechnology, polymer, passive targeting.
Abstract: Site directed drug delivery with high efficacy is the biggest challenge in the area of current pharmaceuticals. Biodegradable polymer-based controlled release nanoparticle platforms could be beneficial for targeted delivery of therapeutics and contrast agents for a myriad of important human diseases. Biodegradable nanoparticles, which can be engineered to load multiple drugs with varied physicochemical properties, contrast agents, and cellular or intracellular component targeting moieties, have emerged as potential alternatives for tracking and treating human diseases. In this review, we will highlight the current advances in the design and execution of such platforms for their potential application in the diagnosis and treatment of variety of diseases ranging from cancer to Alzheimer’s and we will provide a critical analysis of the associated challenges for their possible clinical translation.
Export Options
About this article
Cite this article as:
Marrache Sean, Pathak Kumar Rakesh, Darley L. Kasey, Choi H. Joshua, Zaver Dhillon, Kolishetti Nagesh and Dhar Shanta, Nanocarriers for Tracking and Treating Diseases, Current Medicinal Chemistry 2013; 20 (28) . https://dx.doi.org/10.2174/0929867311320280007
DOI https://dx.doi.org/10.2174/0929867311320280007 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nocturnal Hypertension, Nondipping Phenomenon and Target Organ Damage in Obstructive Sleep Apnea Patients - The Bad and the Worse
Current Respiratory Medicine Reviews An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design Current Evidence Regarding Low-carb Diets for The Metabolic Control of Type-2 Diabetes
Current Diabetes Reviews The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design Multifaceted Approach to Circadian Rhythm: Redox, Oxidative Stress, Melatonin, Antioxidants, Nitric Oxide, Hypoxia, Anesthetics, Cortisol and Cocaine
Current Chemical Biology Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach
Current Respiratory Medicine Reviews Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science Primary and Secondary Hypertriglyceridaemia
Current Drug Targets Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Long Term Ketamine and Ketamine Plus Alcohol Toxicity - What can we Learn from Animal Models?
Mini-Reviews in Medicinal Chemistry